Checkpoint Therapeutics, Inc.
CKPT
Price:
$4.26
Market Cap:
$367.72M
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a tre...[Read more]
Industry
Biotechnology
IPO Date
2016-12-19
Stock Exchange
NASDAQ
Ticker
CKPT
PE Ratio
[-3.33]
ROE
[916.24%]
Current Ratio
[1.91]
Dividend Yield
[0%]
Enterprise Value
[334.68M]
Dividend History
The ROE as of November 2025 (TTM) for Checkpoint Therapeutics, Inc. (CKPT) is 916.24%
According to Checkpoint Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 916.24%. This represents a change of 1.21% compared to the average of 69.93% of the last 4 quarters.
Checkpoint Therapeutics, Inc. (CKPT) Historical ROE (quarterly & annually)
How has CKPT ROE performed in the past?
The mean historical ROE of Checkpoint Therapeutics, Inc. over the last ten years is 21.93%. The current 916.24% ROE has changed 4.08% with respect to the historical average. Over the past ten years (40 quarters), CKPT's ROE was at its highest in in the September 2022 quarter at 787.12%. The ROE was at its lowest in in the June 2022 quarter at -188.93%.
Average
21.93%
Median
-67.38%
Minimum
-308.04%
Maximum
445.47%
Checkpoint Therapeutics, Inc. (CKPT) ROE by Quarter and Year
Discovering the peaks and valleys of Checkpoint Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 191.75%
Maximum Annual ROE = 445.47%
Minimum Annual Increase = -268.88%
Minimum Annual ROE = -308.04%
| Year | ROE | Change |
|---|---|---|
| 2024 | 445.47% | 12.10% |
| 2023 | 397.39% | 23.63% |
| 2022 | 321.43% | -268.88% |
| 2021 | -190.33% | 191.75% |
| 2020 | -65.24% | -50.25% |
| 2019 | -131.13% | -57.43% |
| 2018 | -308.04% | 104.31% |
| 2017 | -150.77% | 116.85% |
| 2016 | -69.53% | 132.21% |
Checkpoint Therapeutics, Inc. (CKPT) Average ROE
How has CKPT ROE performed in the past?
The current ROE of Checkpoint Therapeutics, Inc. (CKPT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
388.09%
5-year avg
181.74%
10-year avg
21.93%
Checkpoint Therapeutics, Inc. (CKPT) ROE vs. Peers
How is CKPT’s ROE compared to its peers?
Checkpoint Therapeutics, Inc.’s ROE is greater than Vigil Neuroscience, Inc. (-138.30%), greater than Orchard Therapeutics plc (-5.12%), less than Revance Therapeutics, Inc. (49.59%), greater than Climb Bio, Inc. (-23.10%), greater than G1 Therapeutics, Inc. (-92.13%), greater than scPharmaceuticals Inc. (-2086.11%), greater than Y-mAbs Therapeutics, Inc. (-24.60%), greater than iTeos Therapeutics, Inc. (-35.52%), greater than SomaLogic, Inc. (-18.59%), greater than Inozyme Pharma, Inc. (-159.97%),
| Company | ROE | Market cap |
|---|---|---|
| -138.30% | $375.71M | |
| -5.12% | $380.11M | |
| 49.59% | $381.02M | |
| -23.10% | $117.96M | |
| -92.13% | $377.75M | |
| -2086.11% | $302.20M | |
| -24.60% | $391.22M | |
| -35.52% | $448.68M | |
| -18.59% | $396.23M | |
| -159.97% | $258.25M |
Build a custom stock screener for Checkpoint Therapeutics, Inc. (CKPT) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Checkpoint Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Checkpoint Therapeutics, Inc. (CKPT) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Checkpoint Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Checkpoint Therapeutics, Inc.'s ROE?
How is the ROE calculated for Checkpoint Therapeutics, Inc. (CKPT)?
What is the highest ROE for Checkpoint Therapeutics, Inc. (CKPT)?
What is the 3-year average ROE for Checkpoint Therapeutics, Inc. (CKPT)?
What is the 5-year average ROE for Checkpoint Therapeutics, Inc. (CKPT)?
How does the current ROE for Checkpoint Therapeutics, Inc. (CKPT) compare to its historical average?